Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults

In a double-blind, phase 3 trial, 663 HIV-infected, virologically suppressed adults were randomized to switch to tenofovir alafenamide (TAF; n = 333) vs. remain on tenofovir disoproxil fumarate (TDF; n = 330), each coformulated with emtricitabine (FTC), while continuing their third agent (boosted pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Raffi, François, Orkin, Chloe, Clarke, Amanda, Slama, Laurence, Gallant, Joel, Daar, Eric, Henry, Keith, Santana-Bagur, Jorge, Stein, David K., Bellos, Nicholaos, Scarsella, Anthony, Yan, Mingjin, Abram, Michael E., Cheng, Andrew, Rhee, Martin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2017
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427981/
https://www.ncbi.nlm.nih.gov/pubmed/28272164
http://dx.doi.org/10.1097/QAI.0000000000001344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427981/
https://www.ncbi.nlm.nih.gov/pubmed/28272164
http://dx.doi.org/10.1097/QAI.0000000000001344

Ejemplares similares